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Abstract
Chronic kidney disease is a serious illness that reduces the life span and quality of
life in diagnosed patients. Despite advancements in medical management, progression to
end-stage renal disease persists. While the renoprotective effects of sodium-glucose
cotransporter-2 inhibitors in diabetes mellitus patients are well-documented, no studies
have examined the efficacy of these drugs in treating renal disease in the absence of
diabetes mellitus. The objective of this trial is to determine whether canagliflozin, a
sodium-glucose cotransporter-2 inhibitor, can improve renal outcomes in patients
with non-diabetic chronic kidney disease. Utilizing a double-blind, randomized control
trial design, we will examine the effects of canagliflozin on patients’ glomerular filtration
rate and progression to end-stage renal disease. We hypothesize that adding canagliflozin
to the standard of care, including a maximum tolerated labeled dose of an angiotensinconverting enzyme inhibitor or an angiotensin II receptor blocker, will decrease the mean
glomerular filtration rate decline per year.

v

Chapter 1 – Introduction
1.1 Background
Epidemiological Data
Kidney disease is among the top fifteen leading causes of death in the United
States.1 Chronic kidney disease (CKD) signifies detrimental changes to the kidneys that
leads to irreversible dysfunction.2 37 million Americans suffer from this disease and it is
estimated that every day approximately 240 patients on dialysis die as a result.3
Furthermore, patients with CKD are five to ten times more likely to die prematurely,
before ever reaching end-stage renal disease and requiring dialysis, due to comorbid
conditions that often accompany their kidney disease.4 To make matters worse, the
prevalence of CKD is likely to be higher than what is reported due to the asymptomatic
nature of the disease in the early stages, preventing early diagnosis for many patients.4
Etiology
Beginning at the age of 40, the glomerular filtration rate (GFR) begins to decline
0.75 mL/min/1.73 m2 per year in healthy individuals,5 but many medical conditions can
precipitate and progress kidney function decline. Diabetes and hypertension are two
common etiologies of CKD and are responsible for approximately two-thirds of CKD
cases in the United States.6 As with many other comorbid disease processes, the danger in
having concomitant diabetes and/or hypertension in addition to CKD is a vicious cycle
that allows each disease process to perpetuate the other.
Current Treatments
Regardless of etiology, the common final pathway in all CKD is end-stage renal
disease in which the patient requires renal replacement therapy in the form of
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hemodialysis or kidney transplantation. The goal of all management strategies in kidney
disease is to prevent or slow the progression of kidney dysfunction. Therapy comes in
many forms including nutritional recommendations, lifestyle modifications, and medical
management. The guidelines of medical nutritional therapy in the context of CKD
suggest limiting daily sodium, an appropriate allowance of protein intake, and the
restriction of phosphorus and potassium.7 Additionally, in all patients regardless of the
extent of kidney damage, smoking cessation and routine physical activity are always
recommended.
Although nutritional and lifestyle modifications are beneficial, medical therapy
remains the cornerstone of management in CKD. One of the strongest independent risk
factors for developing end-stage renal disease is high blood pressure.8 An early study by
Klag et al. demonstrated that patients with blood pressure greater than 200 mmHg
systolic and 130 mmHg diastolic carried a relative risk of 22.1 for developing end stage
renal disease. For this reason, antihypertensive therapy is one of the main strategies in the
management of CKD. It is important to not only control existing hypertension, but to also
prevent hypertension in those who are normotensive.9
Many studies have been designed to investigate which antihypertensive drug class
is most efficacious in slowing renal function decline. Multiple randomized control trials
have demonstrated nephroprotection of angiotensin-converting enzyme (ACE) inhibitors
in the non-diabetic CKD population.10-13 A meta-analysis of several randomized control
trials proved the superiority of ACE inhibitors over other antihypertensives by showing a
risk reduction of 0.7 in the progression of non-diabetic CKD to end-stage renal disease in
those on ACE inhibitor therapy.14 Angiotensin II receptor blockers (ARB) have also been
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shown to be nephroprotective in non-diabetic CKD and have not been shown to be
inferior to ACE inhibitor therapy.15 Tobe et al. indicate that there was no evidence to
suggest that dual therapy with both an ACE inhibitor and an ARB provides superior
nephroprotection over monotherapy.16 Furthermore, in the ONTARGET trial,
investigators sought to determine the safety of dual therapy of both an ACE inhibitor and
ARB and found the combination to actually be harmful, with no therapeutic benefit.17
Other classes of antihypertensive drugs have been extensively studied in the
context of CKD. Although none have been shown to provide as much nephroprotection
as renin-angiotensin-aldosterone system (RAAS) inhibitors, some renoprotective effects
have been appreciated. In the literature category of add-on therapy, research has been
conducted on the addition of calcium channel blockers and mineralocorticoid receptor
antagonists to an ACE inhibitor or an ARB. While there have been studies that show
greater nephroprotection when adding a calcium channel blocker to a RAAS inhibitor, a
recent meta-analysis by Huang et al. showed that the addition of a calcium channel
blocker to an ACE inhibitor or an ARB does not improve the incidence of progression to
end-stage renal disease.18 The addition of a mineralocorticoid receptor antagonist to a
RAAS inhibitor has shown a reduction in surrogate endpoints in both diabetic and nondiabetic CKD.19 Unfortunately, the use of this drug class is accompanied by a significant
increase in risk of hyperkalemia, which is ubiquitously seen in the literature.20,21
While many studies have focused on add-on therapy in the investigation of
effective management of CKD, other studies have focused on comparing different classes
of antihypertensive drugs to the current gold standard, RAAS inhibitors. The authors of
the African American kidney disease and hypertension clinical trial22 studied the effects
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of the ACE inhibitor ramipril, the beta blocker metoprolol, and the dihydropyridine
calcium channel blocker amlodipine as independent drug regimens in the management of
hypertensive kidney disease. The results of the trial demonstrated that ramipril was
superior in delaying the progression of renal disease. Compared to metoprolol, ramipril
offered a 22% risk reduction. When compared to amlodipine, ramipril offered a 38% risk
reduction.23 However, it is important to take into consideration that proteinuria was an
effect modifier for this benefit. In this study, the benefit of ramipril was driven by the
slowing of CKD in those with proteinuria and did not offer much added benefit in
patients without proteinuria.
Diuretics have also been studied in renal insufficiency and the effect that it has on
the progression to end-stage renal disease. In a 2005 post hoc analysis by Rahman et al.,
chlorthalidone (a diuretic) was compared to amlodipine (a calcium channel blocker) and
lisinopril (an ACE inhibitor) to investigate the differences seen in patients’ progression to
end-stage renal disease. Interestingly, the authors found that there was no significant
difference in the development of renal failure between treatment groups.24
Yet another drug that has been studied in kidney disease progression is aliskiren, a
direct renin inhibitor. In the aliskiren and losartan trial in non-diabetic chronic kidney
disease,25 the authors compared three treatment groups: aliskiren, losartan, and aliskaren
plus losartan. While all three groups displayed a reduction in proteinuria, there was no
statistically significant difference in change in GFR from baseline.
While the majority of investigational effort has been focused on antihypertensive
therapeutic modalities, research has also been conducted on different avenues of kidney
disease management. One such avenue is that of alkali therapy. Oftentimes, patients with
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CKD succumb to a state of metabolic acidosis due to the decreased ability of the kidneys
to reabsorb bicarbonate and bind hydrogen molecules to allow for hydrogen excretion. In
order to combat this chronic acidotic state, the administration of sodium bicarbonate has
been used in the management of renal disease. In one study looking at sodium
bicarbonate levels and the progression of CKD, the authors found that patients with
bicarbonate levels less than 22 mEq/L have a 54% greater chance of progression of
kidney dysfunction when compared to patients with serum bicarbonate measurements
within normal limits.26 In another study, the authors used a perspective interventional
approach to examine patients on ACE inhibitor therapy, with a serum bicarbonate level
less than 22 mEq/L, and an eGFR between 20-59 mL/min/1.73m2. Patients were split into
two groups: one to receive sodium citrate and the other to remain on current therapy.
After 24 months, it was shown that the patients adhering to alkali therapy had slower
decline in GFR when compared to the control group.27
Autosomal dominant polycystic kidney disease (ADPKD) is the most common
genetic kidney disease and causes kidney volume growth and cystic abnormalities within
the kidney. ADPKD accounts for 5-10% of patients in renal failure28 and thus
considerable time and effort has been dedicated to researching effective therapies for this
subgroup of CKD. Unfortunately, this subgroup of CKD does not respond to
antihypertensive therapy. The most effective treatment that has been studied is tolvaptan,
a selective vasopressin V2 antagonist. In the TEMPO 3:4 phase III clinical trial, authors
compared tolvaptan versus placebo in the management of ADPKD. After 3 years of
follow-up, it was found that the treatment group benefited from a 49% reduction in the
rate of progression of their renal decline compared to the control group.
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To summarize what has been discussed in this section, the literature supports the
fact that blood pressure control is the mainstay in treatment of CKD, regardless of
whether high blood pressure is the underlying cause of an individual’s renal insufficiency
or if hypertension is a sequela of the disease. Currently, we know that drugs that block
the RAAS are the most effective antihypertensive medication in the CKD population.
ACE inhibitors are more widely used in current medical practice, but ARBs are a
reasonable choice. Other antihypertensive drug classes have been compared to RAAS
inhibitors as well as studied as add-on therapy. The main drug classes that have been
studied include calcium channel blockers, mineralocorticoid receptor antagonists, beta
blockers, diuretics, and direct renin inhibitors. Additionally, therapeutic modalities
outside the antihypertensive realm were discussed, such as alkali therapy and selective
vasopressin V2 antagonists in the context of ADPKD. While some of the aforementioned
drugs have demonstrated nephroprotection, there has yet to be an add-on drug or
alternative medication that has revolutionized CKD management, an advancement that is
desperately needed.
The Promise of Sodium-Glucose Cotransporter-2 Inhibitors
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new class of drug that
recently gained FDA approval for the management of type 2 diabetes mellitus. SGLT2
inhibitors block the reabsorption of glucose in the proximal tubule of the kidney, which
causes glucose to remain in the filtrate and leads to increased glucosuria. Of course, in
diabetes, this drug class logistically works as a management option to aid in the excretion
of glucose in the setting of insulin resistance. In trials on SGLT2 inhibitors, there were
secondary outcomes of renoprotective effects seen across all trials that measured renal
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outcomes. When glucose reabsorption is blocked in the proximal tubule, there is an
increased delivery of solute to the distal tubule which, through glomerulotubular
feedback, causes the afferent arteriole to constrict and produce a decrease in
intraglomerular pressure. Given that diabetic nephropathy is the leading cause of endstage renal disease and SGLT2 inhibitors decrease blood glucose29, it is reasonable that
the majority of research conducted on SGLT2 inhibitors has been focused on diabetes
with and without CKD. However, there is an important gap in the literature regarding the
relationship between non-diabetic CKD and SGLT2 inhibitors. Regardless of etiology,
after initial kidney injury, the kidney undergoes a state of hyperfiltration which leads to
glomerulosclerosis. Glomerulosclerosis then leads to further kidney structure
deterioration and dysfunction causing nephron loss and eventual end-stage renal
disease.30 To date, the most effective method of slowing renal function decline is by
decreasing glomerular pressure, which decelerates the rate of sclerosis and fibrosis
production within the kidney. As discussed in prior sections, the most effective method
we have to decrease intraglomerular pressure is via the inhibition of the RAAS. Given
that SGLT2 inhibitors decrease intraglomerular pressure, it is reasonable to postulate that
the addition of these drugs to a RAAS inhibitor may aid in the battle against CKD.

Figure 1. Natural Course and Cycle of Renal Insufficiency
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1.2 Statement of the Problem
Medical scientists continue to investigate the use of alternate or adjunctive
therapy with hopes of uncovering a drug regimen that is more effective than what is
currently available for renal insufficiency. Aside from the use of an ACE inhibitor or
ARB, there is little evidence in the literature supporting an effective add-on therapy. To
put the need for advancement of treatment in perspective, according to the Global Burden
of Disease data, since 1990, CKD has experienced an 89% increase in global incidence,
an 87% increase in prevalence, and resulted in a 98% increase in cause specific
mortality.31
1.3 Goals and Objectives
The proposed study aims to investigate what effect the addition of canagliflozin to
current pharmacologic management of non-diabetic CKD has on the progression of
kidney disease in adult patients with moderate to severe renal insufficiency. To study the
effect of SGLT2 inhibitors, patients will be divided into two groups: the first receiving a
medication regimen that adheres to the current standard of care and the second group
receiving the standard of care with the addition of canagliflozin, an SGLT2 inhibitor.
This study will utilize change in GFR from baseline as a primary endpoint to compare the
difference in disease course between the control and treatment groups.
1.4 Hypothesis
We hypothesize that among patients 18 years and older with moderate to severe
non-diabetic CKD, the addition of canagliflozin, an SGLT2 inhibitor, to current
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pharmacologic management of CKD will result in significant delay in progression of
renal function decline at 18-month follow-up in comparison to the standard of care alone.
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Chapter 2 – Review of the Literature
2.1 Brief History of Sodium Glucose Cotransporters
In the 19th century, French chemists isolated a chemical compound from the bark
of apple trees that was soon after discovered to have glycosuria effects in those who
ingested the substance.1 This compound is known as phlorizin and can be attributed as
the origin of the now well known drug class called sodium glucose cotransporter (SGLT)
inhibitors. Phlorizin acts as an inhibitor of the SGLT1 protein that is found in both the
kidneys and small intestines. The SGLT proteins are responsible for glucose reabsorption
and thus inhibition of the protein by phlorizin in the kidney leads to glucosuria.
Sodium glucose cotransporter proteins are present in many organs within the
human body. These ubiquitous proteins have been found in the brain, heart, kidneys,
intestines, and many other tissue types within the body. While there are six known
varietals of the sodium glucose cotransporter protein, the homolog of interest in recent
research has been the SGLT2 protein due to its key role in glucose reabsorption within
the kidney where it is responsible for 90-95% of glucose reuptake.2 In an early
investigation by Chen et al., researchers extensively studied the SGLT2 protein using
quantitative RT-PCR methods and found that SGLT2 expression is extremely specific to
the cells located within the kidney.3 This protein’s extensive role in the reabsorption of
glucose coupled with its exclusive expression within the kidney has lead it to be an
attractive and logical focus in the evolving research around diabetes management.
2.2 The Need for Therapeutic Advancement in Type 2 Diabetes Mellitus
The worldwide prevalence of diabetes mellitus is currently 463 million with a
projected prevalence of 578 million by 2030 and 700 million by 2045.4 Prior to the
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development of SGLT2 inhibitors, the cornerstone of medical management for type 2
diabetes mellitus included metformin, insulin, sulfonylureas, and glitazones.5 However,
the need for therapeutic advancement is clear due to the difficulty of disease management
as evident by inevitable worsening of macrovascular and microvascular damage. In a
study by Turner et al. that included 4,075 study participants, the authors showed that after
three years of a monotherapeutic approach, 50% of patients failed to achieve appropriate
blood glucose control and had to begin a multidrug regimen.6 Many antidiabetic agents,
especially when used in combination, often come with a myriad of side effects including
a variety of gastrointestinal disturbances, hypoglycemia, weight gain, and
hyperinsulinemia.7 The most serious of the side effects caused by glucose-lowering
agents is hypoglycemia. Extremely low plasma glucose concentrations pose a significant
health risk to patients evidenced by a greater than fivefold risk of mortality compared to
patients who do not experience hypoglycemic episodes.8
With the combination of inadequate glycemic control despite therapeutic
management and the harsh side effect profiles of the available drugs, it is clear why the
medical community continues to search for improvements in treatments for type 2
diabetes mellitus.
2.3 Studies on SGLT2 Inhibitors in the Type 2 Diabetes Mellitus Population
The current recommendations for newly diagnosed type 2 diabetes mellitus
suggests metformin as the initial drug choice in disease management. However as
discussed in the previous section, management by a single drug is often not a sufficient
deterrent to disease progression. At present there are four drugs within the SGLT2
inhibitor class that are FDA approved for the treatment of type 2 diabetes mellitus either
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as monotherapy or combination therapy. The current approved drugs include
canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.9 In a meta-analysis
performed in 2013, the use of SGLT2 inhibitors was found to have a positive effect on
patients’ serum glucose concentrations. On average, the use of an SGLT2 inhibitor as
monotherapy decreased glucose levels by nearly 80% and, when used in combination
with other glucose-lowering agents, decreased glucose levels by approximately 60%.10
Additionally, SGLT2 inhibitors work under a mechanism that does not interfere with
insulin secretion thus protecting against the risk of hypoglycemia and shielding patients
from increased risk of cardiovascular and other devastating health events.11
In addition to its forefront property of glucose lowering effects, SGLT2 inhibitors
have been shown to have positive outcomes that aid in the management of type 2 diabetes
mellitus. These advantageous sequels of SGLT2 inhibitors include: weight loss due to
osmotic diuresis,12 decreases in systolic and diastolic blood pressures,13 lowering of
triglyceride levels and rises in high-density lipoprotein,14 mitigation of several risk
factors associated with liver disease,15 and diminishment of intraglomerular pressure16
and albuminuria.17
2.4 Secondary Outcomes in Early SGLT2 Inhibitor Clinical Trials
Many earlier trials conducted on SGLT2 inhibitors examined cardiovascular
endpoints as primary outcomes in the type 2 diabetes mellitus population. Through many
of these investigations, renal endpoints were analyzed as secondary outcomes that
eventually led to hypotheses about SGLT2 inhibitors and the relationship they have to
kidney function.

15

One of the first clinical trials that utilized renal outcomes as secondary measures
was the canagliflozin cardiovascular assessment study (CANVAS). This investigation
studied the type 2 diabetes mellitus population and compared cardiac events in a control
group versus a treatment group receiving canagliflozin. This trial enrolled 10,142
participants and had a mean follow-up of approximately 3.6 years. Prespecified
secondary renal outcomes of this trial included progression of albuminuria, change in
GFR, initiation of renal replacement therapy, and renal related death. The results suggest
that canagliflozin has a protective effect on renal outcomes as indicated by slower
progression of albuminuria in the treatment group with a hazard ratio of 0.73 as well as
less frequent occurrences of the other aforementioned renal outcomes calculated as a
composite hazard ratio of 0.60.18
The empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus
patients (EMPA-REG) was a clinical trial that was interested in investigating the benefit
of adding empagliflozin to type 2 diabetes mellitus patients who were at increased risk
for cardiovascular events.19 The trial accrued 7,020 participants and had a 4.6-year
follow-up. While the primary outcome of this trial was time to various pre-determined
cardiovascular events, theories on renal outcomes were able to be formulated from the
data that was collected from the trial results. The statistical results of this trial
demonstrated that both the lower dose (10 mg) regimen and higher dose (25 mg) regimen
of empagliflozin allowed for a statistically significant reduction of renal outcomes
including progression to microalbuminuria, doubling of serum creatinine, initiation of
renal replacement therapy, and worsening of nephropathy.20
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Another interventional clinical trial on an SGLT2 inhibitor was the multicenter
trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events
(DECLARE-TIMI), which sought to investigate the effects dapagliflozin has on
cardiovascular outcomes in the type 2 diabetes mellitus patient population. This study
recruited an impressive 17,190 study participants and used a renal composite endpoint as
a secondary outcome that included a decrease greater than or equal to 40% in eGFR to
less than 60 ml/min/1.732 and/or end-stage renal disease and/or renal or cardiovascular
death. After the trial’s 5.2-year follow-up, the analysis displayed a 46% reduction in GFR
decline by at least 40% to less than 60 ml/min/1.732 in the patient group taking
dapagliflozin when compared to the placebo group.21
2.5 Clinical Trials on SGLT2 Inhibitors with Renal Variables as Primary Outcomes
As suggested in the previous section, many earlier clinical trials on SGLT2
inhibitors served as hypothesis-driving platforms that allowed further investigation into
the effect that SGLT2 inhibitors have on renal function.
Perhaps the most well-known and well regarded trial conducted on an SGLT2
inhibitor with renal primary outcomes is the canagliflozin and renal events in diabetes
with established nephropathy clinical evaluation (CREDENCE) trial.22 In this doubleblind randomized control trial, 4,401 patients were recruited and divided into a
canagliflozin treatment group and placebo group and were followed for approximately
2.6 years. In the analysis, Perkovic et al. found that the renal outcomes including endstage renal disease, doubling of serum creatinine, and renal related death were
significantly lower in the treatment group when compared to the placebo group with a
hazard ratio of 0.70.
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Another clinical trial focused on renal outcome effects of an SGLT2 inhibitor is
the empagliflozin and progression of kidney disease in type 2 diabetes trial.23 The
primary outcome used in this study was worsening nephropathy as defined as progression
or development of microalbuminuria, doubling of serum creatinine, necessity of renal
replacement therapy, and renal related death. The results displayed a hazard ratio of 0.61,
again suggesting that the inhibition of the SGLT2 protein provides renoprotective effects
in the type 2 diabetes mellitus population.
2.6 The Future of SGLT2 Inhibitor Research
After reviewing the literature on SGLT2 inhibitors it is evident that there is a
benevolent relationship between this drug class and not only type 2 diabetes mellitus
disease progression, but also renal health. While it has only been since 2013 that SGLT2
inhibitors have been FDA-approved for the treatment of type 2 diabetes mellitus, there is
currently a large missed opportunity in the use of SGLT2 inhibitors and the possible
benefit they could have on CKD. With the ubiquitous renoprotective effects seen in past
clinical trials and the desperate need for therapeutic options for CKD, the investigation on
SGLT2 inhibitors in non-diabetic renal disease seems like a pertinent and pragmatic next
step in the area of SGLT2 inhibitor research.
2.7 Adverse Effects of SGLT2 Inhibitors
As previously discussed, SGLT2 inhibitors work via an insulin-independent
mechanism that offers protection against hypoglycemia. While this is certainly an
advantage in this drug class, these drugs come with their own adverse effect profile.
The most common adverse event seen in those taking an SGLT2 inhibitor is
genital mycotic infections, which have been reported to occur in both men and women.
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The occurrence of mycotic infections is around 13% in women and 3% in men compared
to approximately 3% and 0.50%, respectively, in control groups.24 While these infections
are inconvenient and uncomfortable for patients, cases are easily resolved with topical or
oral antifungal agents and do not pose harmful long term effects.25
Other commonly noted side effects of SGLT2 inhibitors are the effects of osmotic
diuresis and volume depletion. In the CANVAS trial, results indicated a statistically
significant difference in the event rate of both osmotic diuresis and volume depletion
when comparing the canagliflozin and placebo treatment groups.18 In a pooled analysis of
4 randomized, placebo-controlled, phase 3 clinical trials, the authors investigated the
incidence of osmotic diuresis among the 2,313 study participants and found that most
events due to osmotic diuresis were mild or moderate in severity and led to only three
events of study discontinuation, all in patients older than 65 years. Similarly, the adverse
events reported due to volume depletion were classified as mild to moderate in severity
and led to a single participant study discontinuation. The patients affected by volume
depletion were those under the age of 65 years.26 While it is important to be aware of the
effects of SGLT2 inhibition, providers should not be dissuaded from these medications.
Instead, physicians and other providers should be aware and monitor patients for
symptoms and be cautious when engaging in polypharmacy with drugs such as loop
diuretics.24
Less common but equally as important adverse events seen with SGLT2 inhibitor
use includes acute renal failure, increased incidence of bone fractures, and amputations.24
It has been reported that SGLT2 inhibitors present a risk for acute renal failure with an
odds ratio of 2.88.27 While this increase in renal injury may be due to the diuretic effect
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of the drug class that causes volume depletion and thus a reduction in intraglomerular
perfusion, the disease process of type 2 diabetes and its existing relation with kidney
injury makes it difficult to decipher the culprit of renal insufficiency in clinical trials.
While acute renal injury needs to be monitored, the benefit of SGLT2 inhibitors outweigh
the risks and there are currently no recommendations to discontinue the drug due to a
potential increased risk of kidney injury.27
While the proposed theory that SGLT2 inhibitors increase patient susceptibility to
bone fractures, the evidence is conflicting and points to conclusions of both increased risk
and no additional risk for fractures. The proposed mechanism is that serum phosphate
levels are increased by inhibiting the SGLT2 protein, thereby causing increased fibroblast
growth factor 23 and parathyroid hormone levels, both of which lead to a decline in the
structural integrity of bone.28 In a meta-analysis of 20 studies and 8,286 patients looking
at the pooled risk for canagliflozin, dapagliflozin, and empagliflozin on bone fractures,
the risk ratio was 0.66, 0.84, and 0.57 respectively.29
Lastly, amputations have been noted as a side effect in SGLT2 inhibitor use.
While the mechanism of amputation is unknown, the CANVAS trial exhibited a
statistically significant difference in the incidence of amputations between the treatment
and control groups. In the treatment group, the event rate per 1,000 patient-years was 6.3
while the event rate in the placebo group was 3.4 per 1,000 patient-years (p < 0.001).18
Risk of amputations was not seen in other randomized controlled trials.
Given that SGLT2 inhibitors are still a relatively new class of drugs, all adverse
events must be considered and monitored in patients. That being said, the full realm of
understanding of the mechanism of this drug class is far from complete. Continued
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research, analysis, and observation is needed to lead to definitive statements regarding the
adverse events that this drug group may cause in patients.
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Chapter 3 – Study Methods
3.1 Study Design
We will conduct a randomized, double-blind, placebo-controlled, multicenter
clinical trial among adult patients with CKD but without a concomitant diagnosis of type
2 diabetes mellitus. We will investigate the effectiveness of canagliflozin plus guideline
directed medical therapy compared to placebo plus guideline directed medical therapy for
slowing CKD progression by randomizing patients into one of two groups: treatment or
placebo. We will compare the control group to a placebo group in the context of renal
outcomes over a period of 18 months.
3.2 Study Population and Sampling
The study population will include adults ages 18 years of age and older with CKD
stage three or four. Stage three includes GFRs ranging from 30 to 59 mL/min/1.73m2.
Stage four includes GFRs ranging from 15 to 29 mL/min/1.73m2.1 Pediatric patients will
be excluded due to the nature of disease management differences that often exist between
pediatric patients and their adult counterparts. Additionally, SGLT2 inhibitors are a new
class of drug for which adverse events in the pediatric patient population have yet to be
examined. Only patients with CKD stages three and four will be included due to the
limited time frame that is available for this research study. By only inviting those with
more advanced kidney disease to participate, we hope to enrich the event rate in our
population and more efficiently capture the effect that canagliflozin has on renal
outcomes. Patients will be recruited from all hospitals within the Yale Affiliated
Hospitals Program which include: New Haven, Bridgeport, Danbury, Greenwich, Griffin,
Norwalk, St. Mary’s, and Waterbury hospitals. Our study will be limited to these
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hospitals once again due to time restraints. Having patient recruitment take place within
the state of Connecticut will allow study personnel to easily obtain in-person interviews,
when necessary. Furthermore, the Institutional Review Board process will be more
manageable with all eligible hospitals sharing a common health care network.
3.3 Inclusion Criteria
Study participants will be adult patients between the ages of 18 and 75 years with
stage three or four CKD as defined by current KDIGO guidelines.1 This includes GFR
between 59 and 15 ml/min/1.73m2. Additionally, patients must have a urine albumin to
creatinine ratio greater than 300 milligrams per gram but less than 5,000 milligrams per
gram. In order to be eligible for enrollment, patients must be currently adhering to a daily
regimen of a maximum tolerated labeled dose of an ACE inhibitor or ARB for at least
one month prior to accrual.
3.4 Exclusion Criteria
Patients will be deemed unfit for this study if they have a history or current
diagnosis of type 1 or type 2 diabetes mellitus. Patients may not be in a renal state in
which immunosuppressive management is required. Individuals diagnosed with mild
renal insufficiency or those with end-stage renal disease will not be eligible for
enrollment. Mild renal insufficiency is defined as a GFR 60 ml/min/1.73m2 and greater.
End-stage renal disease includes patients with a GFR less than 15 ml/min/1.73m2 and/or
requiring renal replacement therapy by way of kidney transplantation or hemodialysis.
Patients may not be allowed to enroll if they have liver disease. Patients may also be
excluded if they have stage three or stage four heart failure as defined by the New York
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Heart Association. Finally, refusal to sign the study consent will exclude a patient from
study participation.
3.5 Subject Protection and Confidentiality
This clinical trial will operate within the confines of the Yale New Haven Health
System; thus, appropriate documents will be submitted to Yale University’s Institutional
Review Board and Human Investigation Committee. Yale University is registered under
FDA regulation and operates in compliance with the laws, regulations, and policies set
forward by the administration. Should the committee feel the need to change any detail
within our proposal, we will modify as necessary and re-submit our project.
Our research team believes the advancement of medical knowledge should never
come at the cost of patient confidentiality. Prior to beginning our clinical trial, all study
personnel will be trained in our patient confidentiality protocol and must undergo and
successfully complete training that abides by the standards set forth by the Health
Insurance Portability and Accountability Act (HIPPA).
Pseudonymization will be used to ensure patient identity is kept protected and
separated from study data. Each patient will be assigned an arbitrary number code upon
acquisition of signed consent. Identifying information will be entrusted to the Principal
Investigator and will be held in a locked cabinet file. Duplication and distribution of
documents containing de-identifying information will be prohibited.
Prior to accrual, prospective patients will meet with a trained researcher from our
team. We will ensure each patient is thoroughly educated on canagliflozin including:
possible adverse events while taking an SGLT2 inhibitor, expected time commitment
from the patient, and what we hope to learn from conducting this study. Patients will be
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made aware that they hold the right to discontinue their participation during any phase of
the trial.
3.6 Recruitment
As previously mentioned, patients will be recruited from hospitals that are within
the Yale New Haven Health System and affiliated hospitals. During the recruitment
period, study personnel will be placed at each of the eight hospitals and will be available
to aid in the accrual of study participants and act as a resource to the providers that have a
hand in the recruiting process. Patients that are admitted to internal medicine services as
well as those who visit hospital clinics will be screened for eligibility. Prior to the
enrollment period, hospital team managers will be contacted and informed of the study so
that they may notify the providers with whom they work. Providers will be encouraged to
refer patients to the on-site study coordinators as patients are admitted or seen.
Additionally, study coordinators will be trained and have access to the electronic medical
record system, Epic, used by all participating hospitals. While on-site, patients’ medical
records will be actively reviewed by the coordinators to be screened for eligibility based
on study inclusion and exclusion criteria. Once a patient is deemed eligible, the
coordinator will approach the patient about the possibility of their participation in the
project. If a patient is interested in moving forward with the enrollment process, the
coordinator will consult the patient’s provider to ensure the patient’s safety and ability to
become a study participant. Finally, the coordinator will complete the enrollment process
by thoroughly explaining all aspects of the study to the patient. Once the patient provides
his or her signature of consent, a de-identified patient number will be assigned.
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3.7 Study Variables and Measures
The intervention of interest will be canagliflozin 100 mg oral once daily. The
control will be a placebo pill that will be formulated to be aesthetically identical to the
canagliflozin pill to ensure patients and medicine distributors will be unable to
differentiate between the treatment and placebo. Prior to distribution, the placebo and
canagliflozin pills will be carefully sorted and packaged in personalized blister packaging
to ensure each patient receives the appropriate capsule.
The primary dependent variable will be mean decline in GFR per year. Secondary
outcomes will include end-stage renal disease (defined as dialysis for at least 30 days
and/or GFR less than 15 ml/min/1.73m2), renal related death, hospitalizations due to renal
etiology, and safety endpoints including mycotic infections, bone fractures, and
amputations.
3.8 Methodological Considerations
Experimental Protocol
Subjects who have been deemed qualified to participate in the study will first
undergo a two-week trial that will assess medical compliance. During this time, patients
will be instructed to take a placebo oral capsule once daily and will be closely monitored
by study coordinators via calls and texts, depending on patient preference. Upon
successful completion of this two-week compliance run-in period, patients will then be
randomly assigned in a 1:1 ratio pattern to either the treatment group of canagliflozin or
the placebo control group.
After randomization, patients will return to the outpatient hospital clinics for
follow-up at pre-set intervals. At week 2, patients will be scheduled a call with a
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coordinator to assess tolerance and side effects of the new medication. After initial checkin, patients will visit their respective hospital clinics at weeks 20, 24, 44, 48, 68, and 72.
Visit appointments may be made +/- seven days of the specific recommended date.
Should a patient be unable to have an in-person visit, follow-up appointments may be
conducted via telephone under the discretion of research personnel. During these
appointments, patients will meet with study coordinators who will assess adverse events,
concomitant medication use, and endpoints of interest. Additionally, patients will
undergo phlebotomy laboratory assessments to allow for estimated GFR calculation.
Patients who either choose to discontinue independently or discontinue the study drug
under medical guidance will be encouraged to continue follow-up with coordinators via
planned telephone encounters to allow for continued adverse event monitoring.
Patients will be provided specific instructions regarding time and method of
capsule ingestion. All patients, regardless of treatment group, will be given the same set
of instructions. Study participants will be instructed to take a single capsule once per day
before the first meal of the day, every day, throughout the 18-month follow-up period.
The capsule must be swallowed whole and may not be manipulated in any way (cut,
crushed, chewed, etcetera). Should a patient forget or for some reason cannot take their
dose in the morning, the patient should skip that day’s dose, record the date and reason
for missing the dose, and discuss each skipped dose with study personnel at the
subsequent follow-up visit. Patients are not to discard capsules that are not taken. Study
personnel will maintain a drug log that will account for number of pills dispensed and
pills returned at each visit.
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Figure 2. Study Design

Blinding of Intervention
The treatment and control allocation will be assigned via central randomization
that will utilize computer-generated randomization to place patients in either the
canagliflozin group or placebo group. Prior to randomization, patients will be stratified
based on their estimated GFR in order to match the groups. As previously mentioned,
both the treatment and control capsules will be formulated to look identical and will be
packaged in identical blister packaging. The capsules will be distributed by study
personnel to study participants by de-personalized identification numbers.
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Blinding of Outcome
The blinding of this study is not to be lifted until all study participants have
completed the 18-month treatment course and study data has been secured in the
database. Should there be a medical emergency related to the study drug, blinding may be
broken to ensure safety of the patient as well as other study participants. The Principle
Investigator and Sponsor of this study must be notified immediately if such a situation
occurs. In-depth documentation of the event will be required, as well as continued
follow-up for adverse reactions in study participants.
Adherence
Compliance capabilities will be initially assessed during the two-week
compliance run-in period. The inability to adhere to the medication schedule for at least
five out of seven days per week will disqualify the patient from study participation. After
the compliance phase, adherence to study medication will be assessed at follow-up visits.
The number of pills returned will be compared to number of pills dispatched in order to
assess patient adherence.
Monitoring of Adverse Events
Literature regarding adverse events associated with SGLT2-inhibitors can be
found in chapter two of this proposal. We will monitor and record the occurrence of
known adverse events including mycotic infections, bone fractures, and amputations.
Research personnel will inquire about these events at each follow-up appointment.
Patients will also be encouraged to immediately contact their coordinator should any of
these events occur between appointments. Since SGLT2-inhibitors have yet to be studied
in the non-diabetic population, we will collect data on any adverse event that should
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occur during the 18-month period and will investigate the possible association to the
study drug during analysis.
3.9 Data Collection
Research personnel will be responsible for collecting data at each patient visit
during the 18-month follow-up period. Scheduled follow-up appointments will occur at
weeks 20, 24, 44, 48, 68, and 72. During each visit patients will be asked questions
regarding medication side effects and hospital admissions. Medical record review will
take place at this time if deemed necessary due to a recent hospitalization. Patients will
also undergo a blood draw at each appointment in order to ascertain estimated GFR. The
chronic kidney disease epidemiology collaboration equation (CKD-EPI) will be used to
calculate estimated GFR.2 Patient data will be collected and stored in the password
protected database software, Microsoft Access.
3.10 Sample Size Calculation
To calculate the sample size for this clinical trial we primarily used data points
provided by the canagliflozin and renal events in diabetics with established nephropathy
clinical evaluation (CREDENCE) trial.3 This trial was used as the basis for our
calculation due to its robust sample size, well regarded methods, and widely known
results. It is important to note that while the CREDENCE trial and our trial utilize the
same treatment drug and dose, the CREDENCE trial investigated the impact on CKD
within patients with diabetes mellitus while our study is specifically focused on the nondiabetic population. This difference will be considered when interpreting data and
running statistical analysis, however we believe this is the most reliable study from which
our sample size can be calculated.
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Specific numbers and calculations based off the CREDENCE trial can be found in
appendix D. Assuming a power of 80% and an alpha of 0.05, we calculate a required
sample size of 382 patients per arm, totaling 764 total study participants. In an effort to
decrease the number of participants needed without decreasing the power, we have also
considered assuming a one-sided hypothesis with 80% power and alpha of 0.05. Under
this statistical method and with these assumptions, we calculate a required sample size of
299 patients per arm, totaling 598 study participants.
The first statistical method mentioned would require an average of 16 patients
enrolled per hospital per month. The latter method would require an average of 12
patients enrolled per hospital per month. In the 2018 fiscal year, the Yale New Haven
Heath affiliated hospitals had 124,688 inpatient discharges and 2.4 million outpatient
encounters. We believe the patient load between these eight hospitals will be sufficient to
fulfill our targeted sample size.
We recognize that we are utilizing strong assumptions for our statistical
calculations. We are assuming that our study population has a normal distribution and
that the variance is the same between groups. Additionally, if we feel 598 patients is
more plausible and accessible than 764 patients, we will be assuming a one-sided
hypothesis, which can be interpreted as the assumption that canagliflozin will have a
positive effect on the decline in GFR in our treatment group when compared to the
control group. Should we feel the utilization of a one-sided hypothesis yields a more
attainable patient recruitment goal, we will contemplate ethical considerations that will be
present given the assumptions inherent to a one-sided hypothesis statistical method.
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3.11 Analysis
The primary outcome, change in GFR, is a continuous variable. We are interested
in the difference of means between the treatment group and the control group. To analyze
the difference in means, we will utilize an analysis of covariance in our statistical
methods. The secondary outcomes of this study include end-stage renal disease, renal
related death, hospitalizations due to a renal etiology, and safety endpoints such as
mycotic infections, bone fractures, and amputations. We will utilize Kaplan-Meier curves
to analyze time-to-event occurrences of these outcomes.
3.12 Timeline and Resources
The patient screening for this trial will begin May 1, 2020 and will continue for 6
months, ending on November 1, 2020. However, it may be necessary to postpone these
dates due to the COVID-19 pandemic. After the screening process is complete and
patients have signed the consent paperwork, the medication compliance period will take
place during the month of November. Upon successful completion of the run-in trial, all
patients will be scheduled to begin either canagliflozin or placebo on December 1, 2020.
Follow-up will extend for 18-month, which will conclude on June 1, 2022.
The responsibilities of the Principal Investigator will be divided between Dr.
Jeffrey Turner and Mia Wigley. They will share duties in ensuring compliance with
federal, state, and local laws, institutional policies, and ethical principles. Dr. Jeffrey
Turner will also fill the role of faculty advisor to graduate student Mia Wigley. Ancillary
study personnel will be recruited and trained in accordance with study policy. A total of
eight individuals will be recruited to allow for one study representative at each hospital
location. These research members will be responsible for meeting with patients during
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the consenting process as well as scheduled appointments during the follow-up period.
Recruitment of two Yale undergraduate student research assistants (RA) will take place
during the 6-month screening period. Student RAs will aid in the tasks of data collection,
data entry, and analysis.
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Chapter 4 – Conclusion
4.1 Study Advantages
Many advantages of this proposal lie within the chosen methodology. Using a
multicenter design strengthens the external validity of our trial. By using multiple sites,
we hope to enhance the diversity of our trial population so that our findings are
applicable to the U.S. population. By harnessing greater external validity, we are able to
increase the generalizability of our results. Internal validity of this study is buttressed by
the use of a primary endpoint that is obtained via a standardized equation (CKD-EPI
formula) which will buffer data collection variability between study personnel.
Randomization, stratification, and blinding of study participants will prevent
selection bias and reduce the probability of confounding variables. By putting forth effort
in the randomization process, analysis will be less likely to yield overestimation of effect.
4.2 Study Limitations
The allure of studying an intervention in an original population gives potential for
groundbreaking results. However, the risk of this study lies within the unknown
interaction between a novel patient population and the treatment of interest. For this
reason, the cardinal disadvantage of this study is the possibility of causing harm to
patients. Fortunately, many prior investigations have been focused on canagliflozin and a
very similar patient population, leading to the reasonable assumption that this study
population should have a similar response to the study drug. To protect against patient
harm, adverse events will be closely monitored, research personnel will always be
available to study participants for questions and/or concerns, and frequent study followup appointments will be scheduled.
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The length of this study stands as another disadvantage to this trial. Prior studies
investigating SGLT2 inhibitors have included median follow-up periods longer than the
18-month follow-up allotted for this trial. Median follow-up times for major studies
include: CANVAS trial 3.6 years,1 EMPA-REG trial 4.6 years,2 DECLARE-TIMI trial
5.2 years,3 CREDENCE trial 2.6 years,4 and empagliflozin trial 3.1 years.5 We plan to
diminish the effect of this potential time deficit by enrolling only patients that have
advanced kidney disease as defined by the KDOQI staging,6 which will enrich the event
rate in our population. We understand that by restricting the enrollment to only patients
with advanced CKD, we may be lessening the generalizability of this study. However,
pending the results, if canagliflozin is demonstrated to slow the progression of nondiabetic CKD, longer studies with a wider range of CKD patients may be warranted.
The utilization of a multicenter design allows for greater generalizability,
however there are drawbacks that must be considered in this design decision.
Components of each site that may offer variation include different research coordinators,
physicians, hospital laboratory protocol, etcetera. Research coordinators will be provided
standardized questionnaires and strict instructions regarding the proper conduction of
follow-up appointments and phone calls in an attempt to best standardize the process
across all research sites.
The primary dependent variable (mean decline in GFR per year) will be
ascertained via an estimated GFR predication equation rather than utilizing inulin
clearance, the current gold standard.7 While it is understood that using indirect measures
to calculate the GFR may harm the validity of the study, the timeframe and funds
allocated to this trial do not support the resources needed for utilization of exogenous
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filtration markers. In order to minimize the negative effect that an estimated GFR
calculation may have on the validity of the study results, we have created a follow-up
schedule that allows for pairs of blood collections to take place approximately 30 days
apart. Each pair of estimated GFR values will be averaged and used to monitor a change
in the patient’s GFR. By using the average of two estimated GFR values collected 30
days apart, we are able to minimize the effect of transient events such as hypovolemic or
pre-renal states that may occur on a single day.
4.3 Clinical Implications
CKD is a health concern that not only hinders the quality of life in those who are
diagnosed but is also a major source of medical expenditure in the United States with an
estimated Medicare cost of roughly $49 billion per year.8 Despite considerable effort and
years of clinical trials investigating combination and novel management options for
CKD, there remains a need to bend the curve of disease progression. This trial will be
among the first generation of studies exploring SGLT2 inhibitors in the non-diabetic
CKD population. Future studies will most certainly be warranted but SGLT2 inhibitors
have the potential to have a major impact on patients’ quality of life, length of life, and
healthcare cost at both the individual and national level.
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Appendices
Appendix A. Patient Consent Form

PERMISSION FOR PARTICIPATION IN A RESEARCH PROJECT
310 FR. 2 (2016-1)1
YALE UNIVERSITY SCHOOL OF MEDICINE –YALE-NEW HAVEN
HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – BRIDGEPORT HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – DANBURY HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – GREENWICH HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – GRIFFIN HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – NORWALK HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – ST MARY’S HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – WATERBURY HOSPITAL
Study Title: Canagliflozin to Slow Renal Insufficiency Progression in Non-Diabetic
Chronic Kidney Disease
Principal Investigator: Jeffrey Turner, MD
Co-Principal Investigator: Mia Wigley, PA-SII
Funding Source: Yale Physician Associate Program
Invitation to Participate and Description of Project
We are inviting you to participate in a research study designed to investigate the effect of
canagliflozin on the progression of chronic kidney disease. You have been asked to
participate because you are an adult with stage three or stage four chronic kidney disease,
you do not have a diagnosis of type 2 diabetes mellitus, and you are currently taking a
drug that is classified as either an angiotensin-converting enzyme inhibitor or an
angiotensin II receptor blocker.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This permission
form gives you detailed information about the research study, which a member of the
research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits, and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
Prior to official enrollment, your eligibility will be assessed by your physician and/or a
study coordinator. You will be deemed qualified to participant if you are an adult
between the ages of 18 and 75 years with moderate to severe chronic kidney disease.
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Additionally, you must have a urine albumin to creatinine ratio greater than 300
milligrams per gram but less than 5,000 milligrams per gram. In order to be eligible for
enrollment, you must be currently adhering to a daily regimen of a maximum tolerated
labeled dose of an angiotensin-converting enzyme inhibitor or angiotensin II receptor
blocker for at least one month prior to accrual.
Before the study begins, you will first be assessed for your ability to adhere to a
medication routine on a daily schedule. You will be given a two-week supply of a sugar
pill to assess compliance. You will be instructed to take this pill daily as you do your
other prescribed medications. You will be asked to keep all pills that are not ingested.
Pills should never be thrown away.
At the end of the two-week period, you will be scheduled for an appointment with a study
coordinator and will be asked to bring in all pills that were not taken. At this time, your
eligibility to participate in the study will be determined.
If enrolled in the study, you will be randomly placed into a group that will determine if
you will be given the study medication (canagliflozin) or a placebo pill. A placebo
medication is a capsule designed to look identical to the study medication but does not
have any physiological effect on the body. No one involved in this study, including you,
will know if you have been assigned to the study medication or the placebo pill.
Group placement will be determined by a computer system that will randomly assign you
to a group. The computer program will sort participants equally between the two groups
with considerations in age, gender, race, and kidney function.
Study pills will be administered to you at the end of the two-week trial period. Pills will
be packaged in blister packaging. One compartment equals one day of medication. The
pill is to be taken with your other prescribed medications. Ideally, these are to be taken
before the first meal of each day and are never to be chewed, cut, or crushed. If a daily
dose is skipped, we ask that you do not double up your dose the next day. Maintain
missed doses within their packaging and return packaging and remaining pills at your
subsequent appointment.
Study appointments will be made at weeks 20, 24, 44, 48, 68, and 72. These
appointments can be made within seven days of the suggested date. Should you be unable
to physically attend your appointment, study coordinators will be able to conduct a
telephone appointment to monitor adverse event reactions. If absolutely necessary an
exception within reasonable limits will be made for scheduling an in-person appointment
outside the seven-day range in order to ascertain necessary labs.
During appointments, study coordinators will ask you a series of questions regarding side
effects that you may be experiencing. You are encouraged to contact your study
coordinator at any time should you experience worrisome symptoms between your
appointments.
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In order to monitor your kidney function, you will undergo a blood draw at each of your
appointments. You will also have blood drawn when you are initially screened and the
day you are given your first pack of medication (4 weeks later) in order to obtain your
baseline estimated glomerular filtration rate. Approximately 3 mL of blood will be taken
during each phlebotomy appointment.
At the conclusion of the 18-month follow-up period, you will be notified of your group
assignment. After analysis of study data, you will gain access to all results and literature
that is associated with the study.
You will be informed of any significant new findings that are developed during the
course of your participation in this study that may affect your willingness to continue to
participate.
Risks and Inconveniences
Possible side effects of canagliflozin include genital mycotic infections, volume
depletion, osmotic diuresis, acute renal failure, increased probability of bone fractures,
and amputation.
In previous studies, the risk of mycotic infections was seen in approximately 13% of
women and 3% of men. Should a mycotic infection occur, we will be in contact with your
primary care physician and will ensure you receive appropriate medication to resolve the
infection.
In previous studies, effects of osmotic diuresis and volume depletion was evaluated as
mild to moderate in severity. Management for these side effects is suggested as close
follow-up and symptomatic management. You will be followed closely by both the study
coordinator and your physician who will monitor you for signs and symptoms of these
side effects.
Acute renal failure, bone fractures, and amputations are the least common side effects of
canagliflozin. Close follow-up will aid in the decision of study discontinuation should the
possibility of these risk present at any time.
Canagliflozin is a relatively new drug and has never been studied in the non-diabetic
chronic kidney disease population. For this reason, participation in this study may involve
risks that are currently not known.
Benefits
Participation in the research will help the medical community understand the role that
canagliflozin may have in the management of non-diabetic chronic kidney disease.
We expect this study to have a great impact on and be a contributor to the medical
community. We hope that our collective effort will one day benefit the non-diabetic
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chronic kidney disease community by allowing meaningful decline in the rate of
progression of kidney failure which will allow for deferment in the need for hemodialysis
and/or kidney transplantation.
This study may not benefit you directly.
Economic Considerations
Participation in this research is voluntary.
Monetary compensation will not be given for enrollment and participation.
Parking validation will be given for hospital garage parking for each appointment
throughout enrollment.
Please consider the possible impact that study appointments may have on your work
schedule as we will be unable to compensate for loss of hourly wage/salary.
Treatment Alternatives
There are no alternative treatments to be considered. All participants will continue their
prescribed medical management for their kidney disease as decided by their physician.
The use of canagliflozin will be used as an additive therapy rather than an alternative
therapy.
Confidentiality
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases.
This trial will operate within the confines of the Yale New Haven Health System; thus,
appropriate documents will be submitted to Yale University’s Institutional Review Board
and Human Investigation Committee. Yale University is registered under FDA regulation
and operates in compliance with the laws, regulations, and policies set forward by the
administration.
Our research team believes the advancement of medical knowledge should never be at
the cost of patient confidentiality. Prior to beginning our clinical trial, all study personnel
will be trained in our patient confidentiality protocol and must undergo and successfully
complete training that abides by the standards set forth by the Health Insurance
Portability and Accountability Act (HIPPA).
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Pseudonymization will be used to ensure patient identity is kept protected and separated
from study data. Each patient will be assigned an arbitrary number code upon acquisition
of signed consent. Identifying information will be entrusted to the Principal Investigator
and will be held in a locked cabinet file. Duplication and distribution of documents
containing de-identifying information will be prohibited.
When the results of the research are published or discussed in conferences, no
information will be included that would reveal your identity unless your specific
permission for this activity is obtained.
Representatives from Yale University, the Yale Human Research Protection Program,
and the Yale Human Investigation Committee (the committee that reviews, approves, and
monitors research on human subjects) may inspect study records during internal auditing
procedures. However, these individuals are required to keep all information confidential.
Authorized representatives of the Food and Drug Administration (FDA) and the
manufacturer of canagliflozin may need to review records of individual subjects. As a
result, they may see your name, but they are bound by rules of confidentiality not to
reveal your identity to others.
In Case of Injury
If you are injured while on study, seek treatment and contact the study doctor as soon as
you are able.
Yale School of Medicine and Yale-New Haven Hospital do not provide funds for the
treatment of research-related injury. If you are injured as a result of your participation in
this study, treatment will be provided. You or your insurance carrier will be expected to
pay the costs of this treatment. No additional financial compensation for injury or lost
wages is available.
You do not give up any of your legal rights by signing this form.
Voluntary Participation and Withdrawal
You are free to choose not to participate and if you do decide to become a subject you are
free to withdraw from this study at any time during its course. Refusing to participate or
withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled (such as health care outside the study, the payment for your health
care, and your health care benefits).
If you decide not to participate or if you withdraw, it will not harm your relationship with
your doctors and providers. You would still be treated with standard therapy or, at your
request, referred to a clinic or doctor who can offer appropriate treatment.

45

The researchers may withdraw you from participating in the research, if necessary.
Reasons would include progression of kidney disease/poor response to treatment,
development of serious side effects, or subject non-compliance.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and consider this research and the permission form carefully – as
long as you feel is necessary – before you decide to participate or to not participate in this
research study.
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Authorization and Permission
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement, and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this permission form.
By signing this form, I give permission to the researchers to use (and give out) my
information for the purposes described in this form. By refusing to give permission, I
understand that I will not be able to take part in this research.
Name of Subject: ______________________________

Signature: ____________________________________
Date: ________________________________________

_______________________________________
Signature of Principal Investigator

___________________
Date

or
_________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator, Dr. Jeffrey Turner, at (***) ***-**** or the
Co-Principal Investigator, Mia Wigley, at (***) ***-****.
If after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at (***) ***-****.
If you would like to talk with someone other than the researchers to discuss problems,
concerns, and questions you may have concerning this research, or to discuss your rights
as a research subject, you may contact the Yale Human Investigation Committee at (***)
***-****.

Copyright © 2020 Yale University. All Rights Reserved.
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Appendix B. Estimated GFR Formula

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation for estimating GFR on the Natural Scale*2
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Appendix C. KDOQI Chronic Kidney Disease Definition and Staging

Definition of Chronic Kidney Disease
Criteria3

Definition and Stages of Chronic Kidney Disease

© 2002 National Kidney Foundation, Inc
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Appendix D. Sample Size Calculation
Sample size calculation utilizing CREDENCE trial for base reference4
Treatment
Control
Mean decline in
3.19
4.71
GFR/year
Adjusted mean/month
3.19/12 = 0.27
4.71/12 = 0.39
Standard error
0.15
0.15
Number of patients
2202
2199
Variance
(0.15) * (0.15) * 2202 =
(0.15) * (0.15) * 2199 =
49.55
49.48
Adjusted variance
49.55 → 50/12^2 (round up to be conservative) = 0.35
Effect size
3.19 – 4.71 = -1.52
Adjusted effect size
1.52/12 = 0.12
Sigma
√(0.35) = 0.59
Statistical analysis for two-sided hypothesis sample size calculation5

Statistical analysis for one-sided hypothesis sample size calculation6

© Copyright 2020 Select Statistical Services Limited. All Rights Reserved.
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Appendix E. Detailed Illustration of the Structure and Physiology of a Nephron

Illustrated by Mia Wigley
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